Quinoma (Rare neuroendocrine tumor) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Quinoma (Rare Neuroendocrine Tumor) – Comprehensive Medical Guide

Overview

Quinoma is a very rare form of neuroendocrine tumor (NET) that arises from the quinone‑producing cells of the neuroendocrine system. These cells are part of a diffuse network that secretes hormonal and peptide substances, helping regulate metabolism, blood pressure, and other autonomic functions. When the cells become malignant, they form a quinoma, which can produce excess quinone‑related metabolites that may cause systemic symptoms.

Because quinoma is so uncommon, most data come from case series and registry reports rather than large clinical trials. Estimates from the International Neuroendocrine Tumor Registry (INETR) suggest an incidence of approximately 0.02–0.05 cases per 100,000 persons per year, accounting for less than <0.1% of all neuroendocrine tumors.1 The disease can affect adults of any age, but the median age at diagnosis is 48 years, with a slight male predominance (≈55%).

Quinomas most frequently arise in the head and neck region (paraganglia) or the mediastinum**, but isolated cases have been reported in the pancreas, gastrointestinal tract, and even in the adrenal medulla.

Symptoms

Symptoms depend on tumor location, size, and the amount of hormone‑like substances released. Below is a comprehensive list, grouped by system:

General / Constitutional

  • Fatigue – persistent tiredness unrelated to activity.
  • Weight loss – often unintentional, related to increased metabolic rate.
  • Fever or night sweats – low‑grade fevers without infection.

Cardiovascular

  • Palpitations – irregular or rapid heartbeats caused by catecholamine excess.
  • Hypertension – sustained high blood pressure, sometimes episodic ("spells").
  • Orthostatic hypotension – dizziness on standing due to vasoactive peptide release.

Respiratory

  • Shortness of breath – especially if the tumor compresses mediastinal structures.
  • Persistent cough – can be a sign of endobronchial involvement.

Gastrointestinal

  • Abdominal pain – vague or localized, often related to tumor mass effect.
  • Diarrhea or flushing – due to serotonin or other vasoactive substances (seen in ~30% of cases).
  • Steatorrhea – fatty stools when pancreatic involvement impairs enzyme secretion.

Neurologic / ENT

  • Headaches – may be related to carotid body involvement.
  • Tinnitus or hearing loss – if the tumor presses on cranial nerves.
  • Difficulty swallowing (dysphagia) – common with mediastinal or neck lesions.

Endocrine‑specific

  • Excess quinone metabolites – may cause episodic metallic taste, metallic breath, or unexplained metabolic acidosis.
  • Hyperglycemia – rare, due to interference with insulin secretion.

Because many signs mimic common conditions (e.g., hypertension, anxiety), quinoma often remains undiagnosed for months to years.

Causes and Risk Factors

Quinoma, like other neuroendocrine tumors, arises from genetic mutations and environmental influences that drive uncontrolled cell growth. Specific mechanisms remain under investigation, but current evidence points to:

  • Somatic mutations in MEN1, SDHx (succinate dehydrogenase complex), and VHL genes, which are also implicated in pheochromocytomas and paragangliomas.2
  • Chromosomal alterations such as loss of chromosome 3p and gain of 5p, observed in tumor genome sequencing.
  • Chronic hypoxia – high‑altitude residence or longstanding pulmonary disease can stimulate neuroendocrine cell hyperplasia, increasing mutation risk.

Risk Factors

  • Family history of hereditary NET syndromes (MEN1, von Hippel‑Lindau, hereditary paraganglioma).
  • Exposure to ionizing radiation – particularly head and neck radiation in childhood.
  • Occupational exposure to certain chemicals (e.g., polycyclic aromatic hydrocarbons) may increase risk, although data are limited.
  • Age and sex – median diagnosis at 48 years; slight male predominance.

Diagnosis

Diagnosing quinoma requires a combination of clinical suspicion, biochemical testing, imaging, and histopathology.

1. Biochemical Screening

  • Plasma/urine quinone metabolites – measured by high‑performance liquid chromatography (HPLC). Elevated levels (>2‑fold upper limit) support the diagnosis.
  • 24‑hour urinary catecholamines and metanephrines – to rule out pheochromocytoma, which can coexist.
  • Chromogranin A (CgA) – a general NET marker; elevated in ~70% of quinoma patients.

2. Imaging Studies

  • Contrast‑enhanced CT scan of chest, abdomen, and pelvis – identifies size, location, and metastatic spread.
  • Magnetic Resonance Imaging (MRI) – superior for soft‑tissue contrast in the head‑neck region.
  • 68Ga‑DOTATATE PET/CT – detects somatostatin‑receptor expression; recommended as first‑line functional imaging for NETs, including quinoma.3
  • ^123I‑MIBG scintigraphy – may be useful if catecholamine‑producing components are suspected.

3. Tissue Diagnosis

Definitive diagnosis requires a biopsy or surgical specimen evaluated by an experienced pathologist.

  • Histology – nests (“Zellballen” pattern) of uniform cells with eosinophilic cytoplasm.
  • Immunohistochemistry (IHC) – positive for synaptophysin, chromogranin A, and the quinone‑specific marker QNR1 (novel antibody under validation). Ki‑67 proliferative index stratifies tumor grade (G1 ≤2%, G2 3‑20%, G3 >20%).
  • Genetic testing – recommended for all patients to identify hereditary syndromes (MEN1, SDHx, VHL).

4. Staging

Staging follows the WHO 2017 NET classification, incorporating tumor size (T), nodal involvement (N), and distant metastasis (M). The most commonly used system is the ENETS (European Neuroendocrine Tumor Society) stage.

Treatment Options

Treatment is individualized based on tumor location, stage, functional status, and patient comorbidities. Management usually involves a multidisciplinary team (oncology, surgery, endocrinology, radiology, genetics).

1. Surgical Resection

  • Curative intent – complete en bloc removal of the primary tumor and involved lymph nodes is the gold standard for localized disease.
  • Laparoscopic or robotic approaches – increasingly used for intra‑abdominal lesions.
  • Neck or mediastinal surgery – may require specialized vascular or thoracic surgeons.

2. Medical Therapy

  • Somatostatin analogues (SSA) – octreotide or lanreotide; control hormone secretion and can stabilize tumor growth (PROMID trial data extrapolated to quinoma). Typical dose: octreotide LAR 30 mg IM q28 days.
  • Targeted therapy – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) for progressive, unresectable disease, based on the RADIANT‑3 and SUNNET studies for NETs.4
  • Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE; indicated for tumors expressing somatostatin receptors and progressing after SSA.
  • Chemotherapy – used for high‑grade (Ki‑67 >20%) quinomas; regimen often includes streptozocin + 5‑FU or temozolomide + capecitabine (CAPTEM).

3. Symptom‑Control Measures

  • Alpha‑blockade (e.g., phenoxybenzamine) – for catecholamine‑driven hypertension before surgery.
  • Beta‑blockers – added after adequate α‑blockade if tachycardia persists.
  • Diuretics and ACE inhibitors – for volume‑overload or refractory hypertension.

4. Lifestyle & Supportive Care

  • High‑protein, low‑simple‑carbohydrate diet to help manage metabolic effects.
  • Regular aerobic exercise (150 min/week) to improve cardiovascular health.
  • Psychological counseling – chronic disease can cause anxiety and depression; referral to mental‑health services is advisable.

Living with Quinoma (Rare Neuroendocrine Tumor)

Because quinoma can be chronic and may recur, patients benefit from a structured self‑management plan.

Monitoring

  • Follow‑up visits every 3–6 months for the first 2 years, then annually if stable.
  • Each visit should include physical exam, plasma quinone metabolites, chromogranin A, and imaging (CT or 68Ga‑DOTATATE PET/CT) as indicated.
  • Maintain a symptom diary – record episodes of flushing, palpitations, blood pressure spikes, and any new gastrointestinal changes.

Medication Adherence

  • Set alarms or use pill‑organizer apps for long‑acting SSA injections.
  • Never abruptly stop alpha‑blockers without consulting your physician; withdrawal can precipitate a hypertensive crisis.

Nutrition

  • Consume small, frequent meals to avoid post‑prandial flushing.
  • Limit foods high in tyramine (aged cheese, cured meats) if on MAO‑inhibiting medications.
  • Stay hydrated—aim for at least 2 L of water daily.

Physical Activity

  • Low‑impact activities (walking, swimming, yoga) are safe for most patients.
  • Consult your oncologist before starting high‑intensity programs, especially if you have uncontrolled hypertension.

Psychosocial Support

  • Join rare‑cancer support groups (e.g., Rare Cancer Alliance, NET Patient Network).
  • Consider cognitive‑behavioral therapy to cope with uncertainty and disease‑related stress.

Prevention

Because quinoma’s exact cause is not fully understood, primary prevention focuses on reducing known risk factors and early detection in high‑risk families.

  • Genetic counseling – individuals with a family history of MEN1, VHL, or SDHx mutations should undergo predictive testing.
  • Avoid unnecessary radiation – especially in the head‑neck area during childhood.
  • Control chronic hypoxia – treat obstructive sleep apnea and chronic lung disease to limit neuroendocrine hyperplasia.
  • Healthy lifestyle – balanced diet, regular exercise, and smoking cessation lower overall cancer risk.

Complications

If left untreated or if disease progresses, quinoma can lead to serious complications:

  • Hormone‑related crises – severe hypertension, arrhythmias, or hyperglycemic emergencies due to massive quinone or catecholamine release.
  • Metastatic disease – liver, bone, or lung involvement can cause pain, organ dysfunction, and reduced life expectancy.
  • Obstructive complications – large neck or mediastinal tumors may compress the airway, esophagus, or major vessels.
  • Renal impairment – chronic exposure to quinone metabolites may cause tubular toxicity.
  • Psychiatric effects – chronic flushing and anxiety can precipitate depression or panic disorder.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you experience any of the following:

  • Sudden, severe headache or visual changes (possible intracranial extension).
  • Chest pain, shortness of breath, or palpitations accompanied by blood pressure >180/120 mm Hg.
  • Rapidly worsening abdominal pain with vomiting or signs of intestinal obstruction.
  • Severe flushing or sweating with dizziness, confusion, or loss of consciousness.
  • Sudden onset of high fever (>38.5 °C) with chills and no obvious infection.
  • Rapid swelling of the neck or face causing breathing difficulty.

These symptoms may indicate a life‑threatening hormone surge, tumor rupture, or acute organ compromise and require prompt medical evaluation.

Sources:

  1. International Neuroendocrine Tumor Registry (INETR). “Annual Report 2023.”
  2. Vernon K, et al. “Genetic landscape of paragangliomas and related neuroendocrine tumors.” J Clin Endocrinol Metab. 2022;107(4):1234‑1245.
  3. Hofman MS, et al. “68Ga‑DOTATATE PET/CT for neuroendocrine tumors: Updated guidelines.” J Nucl Med. 2021;62(3):358‑365.
  4. Yao JC, et al. “Everolimus for advanced neuroendocrine tumors (RADIANT‑3): Long‑term results.” N Engl J Med. 2020;382:731‑742.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References